The University of Wisconsin Carbone Cancer Center (UWCCC) seeks continued funding for years 44-48 in pursuit of its mission to dramatically reduce the burden of cancer within and beyond its catchment. The UWCCC, which is a matrix center within the University of Wisconsin School of Medicine and Public Health (SMPH), is composed of 198 faculty members from 38 departments and 8 schools of the University of Wisconsin-Madison (UW). Our members pursue cancer care, research and education through 6 scientific programs (Human Cancer Virology, Cancer Genetic and Epigenetic Mechanisms, Tumor Microenvironment, Imaging and Radiation Sciences, Developmental Therapeutics, and Cancer Prevention and Control) supported by 10 Shared Resources. During the period 2012-2016, our members published 3324 cancer relevant manuscripts (with 66% collaborative) and were supported by $63.7M (Direct) peer-reviewed cancer relevant funding and $16.6M (Direct) non peer-reviewed funding (as of December 31, 2016). The UWCCC will accomplish this mission through nurturing a supportive cancer community, reliable infrastructure, and efficient resources. The UWCCC worked to decrease the burden of cancer in our catchment and beyond through prioritized research areas (e.g. innovative therapies and biomarkers, cancer imaging and expanded population-based cancer research), enhanced research platforms (e.g. improved clinical research infrastructure and shared resources), increased efforts to build mission-related philanthropy and expanded local to global partnerships.

Public Health Relevance

The University of Wisconsin Carbone Cancer Center (UWCCC), which is a matrix center within the University of Wisconsin School of Medicine and Public Health (SMPH), seeks to dramatically reduce the burden of cancer within and beyond our catchment. Specifically, the UWCCC will do this by decreasing cancer incidence and mortality among populations within our catchment area and beyond, including our minority and underserved populations. We will facilitate pursuit of this goal through partnerships with other health delivery systems and state and community agencies for dissemination of evidence-based findings. The UWCCC will accomplish the aforementioned goals through nurturing a supportive cancer community, reliable infrastructure and efficient resources. The UWCCC has started to decrease the burden of cancer in our catchment and beyond through prioritized research areas (e.g. innovative therapies and biomarkers, cancer imaging and expanded population- based cancer research), enhanced research platforms (e.g. improved clinical research infrastructure and shared resources), increased efforts to build mission-related philanthropy and expanded local to global partnerships.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-45
Application #
9706735
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2023-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65
Wargowski, Ellen; Johnson, Laura E; Eickhoff, Jens C et al. (2018) Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer 6:21
Bednarz, Bryan; Grudzinski, Joseph; Marsh, Ian et al. (2018) Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys 114:450-459
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
van den Broek, Jeroen J; van Ravesteyn, Nicolien T; Mandelblatt, Jeanne S et al. (2018) Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 38:140S-150S
Lu, Zhanping; Hong, Courtney C; Kong, Guangyao et al. (2018) Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. Cell Rep 22:1545-1559
Shea, Michael P; O'Leary, Kathleen A; Fakhraldeen, Saja A et al. (2018) Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER?+ Mammary Carcinomas. Cancer Res 78:1672-1684
Schrager, Sarina; Burnside, Elizabeth (2018) Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools. J Womens Health (Larchmt) :
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112

Showing the most recent 10 out of 1528 publications